Home /
News
Stay at the forefront of drug delivery innovation in the contract development and manufacturing organization (CDMO) space. Explore our latest news and announcements, where the demands of today meet the possibilities of tomorrow.
Company announcement
Video tour | Explore Kindeva’s US manufacturing network
News filter
Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl
ORLANDO, Fla., September 7, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company’s patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl transdermal system, with their development and manufacturing partner, Kindeva Drug Delivery. Studies at Kindeva Drug Delivery have demonstrated that Nutriband’s proprietary transdermal aversive coating […]
Read moreKindeva Drug Delivery acquisition of iPharma Labs Inc. completed
June 16, 2022 Woodbury, MN — Kindeva Drug Delivery (“Kindeva”) has completed the acquisition of iPharma Labs, Inc. (“iPharma”) located in San Francisco’s Bay Area. This acquisition combines iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in developing, commercializing, and manufacturing […]
Read moreKindeva Drug Delivery announces collaboration with Synopsys
June 14, 2022 Woodbury, MN — Kindeva Drug Delivery (Kindeva) has announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware™ automated software solutions to assist in creating a state-of-the-art system for accurately measuring Kindeva’s microstructured transdermal system (MTS) arrays. This collaboration will enable fast and accurate measurements of Kindeva’s MTS arrays by […]
Read moreKindeva and BOL Pharma using low Global Warming Potential (GWP) Propellant in development of Inhaled Cannabinoid products
May 11, 2022 St. Paul, MN — Kindeva Drug Delivery (Kindeva) and Breath of Life International (BOL Pharma or BOL) have agreed to the use of low GWP propellants in multiple inhaled cannabinoid products. Kindeva will develop novel formulations of BOL Pharma’s cannabinoid-based drug products delivered by Kindeva’s pressurized metered-dose inhaler (pMDI) technology using the […]
Read moreKindeva Drug Delivery to acquire iPharma Labs Inc.
April 29, 2022, Woodbury, MN — Kindeva Drug Delivery (“Kindeva”), has entered into a definitive agreement to acquire iPharma Labs, Inc. (“iPharma”) located in San Francisco’s Bay Area. This acquisition will combine iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in […]
Read moreVirpax Pharmaceuticals selects Kindeva Drug Delivery as development partner for Diclofenac pMDI commercialization
April 27, 2022 Woodbury, MN — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) and Kindeva Drug Delivery will work together to advance the clinical program of the Virpax-developed Diclofenac topical spray film (Epoladerm™) in the United States. The product is being studied for the treatment of pain associated with osteoarthritis of the knee. Using Kindeva’s state-of-the-art facilities […]
Read moreLive-attenuated VEEV vaccine delivered by iDNA using microneedles is immunogenic in rabbits
March 11, 2022 – Medigen, Inc’s Dr. Irina Tretyakova and Dr. Peter Pushko in collaboration with Dr. John Vasilakos (Kindeva) and Dr. Tomai (3M) have published the manuscript titled Live-Attenuated VEEV Vaccine Delivered by iDNA using Microneedles is Immunogenic in Rabbits in Frontiers in Tropical Diseases, 2 Mar 2022. The authors demonstrate induction of neutralizing […]
Read moreViatris Inc. announces receipt of the first FDA approval for generic version of Symbicort® inhalation aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate inhalation aerosol), in partnership with Kindeva
PITTSBURGH and ST. PAUL, Minn., March 16, 2022 — Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for BreynaTM (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca’s Symbicort®. Breyna, […]
Read more
Kindeva Drug Delivery to manufacture new, greener inhalers at UK manufacturing site to help cut carbon emissions
February 16, 2022 – One of the UK’s biggest asthma inhaler manufacturers has today announced its intention to invest in its UK manufacturing site to support the development of a new generation of greener inhalers, designed to help support the National Health Service (NHS) to cut a contributor to its emissions. The new inhalers will […]
Read moreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.